retatrutide trial results Lilly's triple agonist achieves 16.8% weight loss in phase 3 retatrutide clinical trial stage Retatrutide

If you have diabetes, reflux, or take GLP-1 weight-loss medications or peptides , you must discuss this with your doctor in advance, as the fasting rules may be slightly different for you

That information, she says, will hopefully lead to a better understanding of how best to use GLP-1 drugs against cancer

This study investigated whether GLP-1 RA therapy reduces one-year all-cause mortality and major adverse cardiovascular events (MACE) in non-diabetic obese RA patients

Mild side effects like nausea or digestive discomfort often subside as your body adjusts

For retatrutide, no such data are publicly available

Its influence reaches further than just shedding pounds and demonstrates improvements in cholesterol, liver fat, and additional metabolic concerns